Medtronic Advances Abbott CGM Partnership with FDA Submissions

Medtronic has submitted 510(k) applications to the U.S. FDA for clearance of an interoperable insulin pump as part of its ongoing collaboration with Abbott.

Key submissions include:
- MiniMed 780G pump as an Alternate Controller Enabled (ACE) insulin pump
- SmartGuard algorithm as an interoperable automated glycemic controller (iAGC)

The devices are intended for integration with Abbott’s latest continuous glucose monitoring (CGM) platform.

Pending FDA clearance, this system will be sold exclusively by Medtronic and include smart dosing technologies for both automated insulin delivery and multiple daily injections.

Medtronic emphasized the urgency and significance of expanding CGM choices for people with diabetes and aims to bring enhanced system options to market following regulatory approval.